West Oak Capital’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

West Oak Capital’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10	Closed	-$533	–	311
2018 Q4	$533	Hold	10	–	–	﹤0.01%	327
2018 Q3	$573	Hold	10	–	–	﹤0.01%	354
2018 Q2	$585	Hold	10	–	–	﹤0.01%	323
2018 Q1	$473	Buy	+10	New	+$504	﹤0.01%	340

Other funds holding BCLI

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

West Oak Capital's BCLI Position: Q1 2019 in Review

West Oak Capital sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2019, closing a stake of 10 shares — an estimated $533 sold.

West Oak Capital first reported a position in BCLI in Q1 2018 and held it in 4 quarters. The position peaked at $585 in Q2 2018. 38 funds tracked by Wall St. Rank hold BCLI as of Q1 2019.

West Oak Capital reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2019 after selling out during the quarter.
West Oak Capital sold 10 BRAINSTORM CELL THERAPUTC shares in Q1 2019, an estimated $533.
West Oak Capital first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2018 and held it in 4 quarters.
West Oak Capital's BRAINSTORM CELL THERAPUTC position peaked at $585 in Q2 2018.
38 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2019.

Based on West Oak Capital's 13F filing for Q1 2019, filed 3 Apr 2019.